Cipher Pharmaceuticals Inc.

As of June 30, 2026, Cipher Pharmaceuticals Inc. carries a market capitalization of 412.67M, placing it among publicly traded companies globally. Its enterprise value stands at 400.26M, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

Cipher Pharmaceuticals Inc.'s next confirmed earnings release is scheduled for November 5, 2026.

As of June 30, 2026, Cipher Pharmaceuticals Inc. has 25.39M shares outstanding.

As of June 30, 2026, Cipher Pharmaceuticals Inc. trades at a trailing price-to-earnings ratio of 10.01. The price-to-sales ratio is 5.85, and the price-to-book ratio stands at 2.12.

As of June 30, 2026, Cipher Pharmaceuticals Inc. trades at an EV/EBITDA multiple of 10.59 - the valuation measure that neutralizes differences in capital structure, tax rates, and depreciation policy, making it the standard yardstick for comparing companies across an industry. The EV/Sales ratio of 5.68 reflects the premium investors pay for the company's revenue stream, a useful check when earnings are depressed or negative. Its EV/EBIT multiple of 14.51 values the business against core operating earnings after depreciation, a stricter test than EV/EBITDA for capital-intensive businesses. These enterprise value multiples are built on an enterprise value of 400.26M versus a market cap of 412.67M, with the gap driven by net debt and cash on the balance sheet.

As of June 30, 2026, Cipher Pharmaceuticals Inc. maintains a current ratio of 1.59, meaning it holds 1.6x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is 0.27, indicating conservative leverage, while an interest coverage ratio of 522.12 demonstrates strong ability to service its debt obligations.

Over the twelve months ended June 30, 2026, Cipher Pharmaceuticals Inc. posted a return on equity (ROE) of 23.50, showing how much profit the company earns on every dollar of shareholder capital. Return on assets (ROA) stands at 18.75, measuring how efficiently the asset base is converted into earnings. The company generates approximately 1.48M in revenue per employee across its workforce of 47.50, a quick read on workforce productivity versus industry peers. Inventory turnover of 1.25 indicates how many times Cipher Pharmaceuticals Inc. sells and replaces its inventory over a year, a key working capital efficiency ratio.

Over the twelve months ended June 30, 2026, Cipher Pharmaceuticals Inc. recorded an income tax benefit of -16.35M rather than an expense, typically from losses, carryforwards, or the release of a tax provision. Taxes are levied on pretax income of 24.79M, leaving 41.14M in net income after tax - the gap is what shifts in the tax rate do to reported earnings and EPS.

As of the close on October 15, 2026, Cipher Pharmaceuticals Inc.'s stock has declined approximately 5.75% over the past 52 weeks. The 50-day moving average sits at 15.83, while the 200-day moving average is 14.81.

Over the twelve months ended June 30, 2026, Cipher Pharmaceuticals Inc. generated 70.43M in revenue and converted that into 41.14M in net income, yielding earnings per share of 1.58. EBITDA reached 37.79M, while operating income came in at 28.00M.

As of June 30, 2026, Cipher Pharmaceuticals Inc. holds 12.93M in cash and equivalents against 520,850.07 in total debt, resulting in a net debt position of -12.93M. Total book value stands at 194.79M, with working capital of 16.28M providing operational flexibility.

Cipher Pharmaceuticals Inc. produced 38.40M in operating cash flow over the twelve months ended June 30, 2026. After subtracting -1.33M in capital expenditures, free cash flow totaled 37.08M - equivalent to 1.46 per share.

Over the twelve months ended June 30, 2026, Cipher Pharmaceuticals Inc. posted a gross margin of 81.40, reflecting its pricing power and cost economics. The operating margin of 39.76 and net profit margin of 58.42 provide insight into operational efficiency.

These figures cover the twelve months ended June 30, 2026. Free cash flow yield stands at 8.79, showing how much cash the business generates relative to its market value - dividends covered by free cash flow are generally more durable than those funded by debt. Total shareholder yield reaches 9.69, combining dividends paid with share buybacks and debt reduction for a fuller picture of capital returned to Cipher Pharmaceuticals Inc. shareholders.

As of June 30, 2026, Cipher Pharmaceuticals Inc. has an Altman Z-Score of 12.92, well above the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.